Antibiotic resistance (AR) remains a leading health challenge, affecting millions of the global population, creating economic burdens and is responsible for most disease-related morbidity and mortality worldwide. It is characterized by the ability of pathogenic microorganisms to evade the pharmacological actions of antibiotics, and this occurs incessantly through multi-faceted, complex and dynamic pathways.
Relevant drug-resistant and multi-drug-resistant (MDR) microorganisms are responsible for posing clinical challenges in the treatment of microbial infections by evolving the AR-inclined pathomechanisms. Notably, these include the modifications of cellular targets, genetic variability encoding, formation of bio-film and inaccessible sites for drugs, and catalytic metabolic destruction of antibiotics.
Importantly, the unpleasant AR events affect all currently available antibiotic classes including the strong types such as cephalosporins, carbapenems, β-lactams, fluoroquinolones and glycopeptide antibiotics, even in combined forms. Moreover, the mechanisms of AR development are mostly facilitated through the action of defensive macromolecules and enzymes produced by the pathogens e.g. the extended-spectrum β-lactamases (ESBL) produced by Enterobacteriaceae. These make the development of new antibiotics with enhanced efficacy through effective inhibitory mechanisms on the AR-mediated organisms, enzymes and pathways remain imperative.
Submissions of research articles, mini-reviews, reviews, systematic reviews, commentaries and notes that fit into the scope of this themes are welcome, including:
• studies on mechanisms of AR development.
• structural biology of AR-mediated macromolecules (proteins and enzymes), bioinformatics and in silico studies
• design and development of new antimicrobial agents
• inhibition of pathogenic bacteria and fungi, AR-related proteins/enzymes and pathways
• reports on chemically characterized natural products and synthetic compounds with antimicrobial potential (GC-MS, NMR, HPLC, LC-MS and FTIR characterization techniques are acceptable)
• antimicrobial peptide, drug delivery
• nutrition, immune system and AR
• pre-clinical in vitro and in vivo antimicrobial experiments
• evolution of ESBLs and other defensive bacterial enzymes
• pharmacodynamics, pharmacokinetics and toxicity of new and existing antibiotics
• antimicrobial studies of existing drugs and their formulations including complexes, conjugates and nanostructures.
• toxicity of existing and emerging antimicrobial agents.
• eubiosis and microbiota
• repurposable drugs as potential antibiotics
Keywords:
Antimicrobial Resistance (AMR), Low and Middle-Income Countries (LMICs), Multidrug-resistant bacteria, Antibiotic drug development, Mechanisms of resistance, Pharmacology, Enzyme inhibition, β-lactamases, In vitro and in vivo analyses, Molecular and structural biology, Toxicity, Molecular docking, Molecular dynamics, natural product and synthetic antibiotics, Antibiotic resistance, Microbiota, Nutrition and immune system
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Antibiotic resistance (AR) remains a leading health challenge, affecting millions of the global population, creating economic burdens and is responsible for most disease-related morbidity and mortality worldwide. It is characterized by the ability of pathogenic microorganisms to evade the pharmacological actions of antibiotics, and this occurs incessantly through multi-faceted, complex and dynamic pathways.
Relevant drug-resistant and multi-drug-resistant (MDR) microorganisms are responsible for posing clinical challenges in the treatment of microbial infections by evolving the AR-inclined pathomechanisms. Notably, these include the modifications of cellular targets, genetic variability encoding, formation of bio-film and inaccessible sites for drugs, and catalytic metabolic destruction of antibiotics.
Importantly, the unpleasant AR events affect all currently available antibiotic classes including the strong types such as cephalosporins, carbapenems, β-lactams, fluoroquinolones and glycopeptide antibiotics, even in combined forms. Moreover, the mechanisms of AR development are mostly facilitated through the action of defensive macromolecules and enzymes produced by the pathogens e.g. the extended-spectrum β-lactamases (ESBL) produced by Enterobacteriaceae. These make the development of new antibiotics with enhanced efficacy through effective inhibitory mechanisms on the AR-mediated organisms, enzymes and pathways remain imperative.
Submissions of research articles, mini-reviews, reviews, systematic reviews, commentaries and notes that fit into the scope of this themes are welcome, including:
• studies on mechanisms of AR development.
• structural biology of AR-mediated macromolecules (proteins and enzymes), bioinformatics and in silico studies
• design and development of new antimicrobial agents
• inhibition of pathogenic bacteria and fungi, AR-related proteins/enzymes and pathways
• reports on chemically characterized natural products and synthetic compounds with antimicrobial potential (GC-MS, NMR, HPLC, LC-MS and FTIR characterization techniques are acceptable)
• antimicrobial peptide, drug delivery
• nutrition, immune system and AR
• pre-clinical in vitro and in vivo antimicrobial experiments
• evolution of ESBLs and other defensive bacterial enzymes
• pharmacodynamics, pharmacokinetics and toxicity of new and existing antibiotics
• antimicrobial studies of existing drugs and their formulations including complexes, conjugates and nanostructures.
• toxicity of existing and emerging antimicrobial agents.
• eubiosis and microbiota
• repurposable drugs as potential antibiotics
![]()
Keywords:
Antimicrobial Resistance (AMR), Low and Middle-Income Countries (LMICs), Multidrug-resistant bacteria, Antibiotic drug development, Mechanisms of resistance, Pharmacology, Enzyme inhibition, β-lactamases, In vitro and in vivo analyses, Molecular and structural biology, Toxicity, Molecular docking, Molecular dynamics, natural product and synthetic antibiotics, Antibiotic resistance, Microbiota, Nutrition and immune system
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
